New combo therapy targets hard-to-treat HER2-positive cancers
NCT ID NCT06364410
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 28 times
Summary
This early-phase study is testing whether adding a drug called azenosertib to the existing cancer drug trastuzumab deruxtecan (T-DXd) is safe and effective for people with HER2-positive stomach, esophageal, or other solid tumors that have spread or can't be removed by surgery. About 48 adults whose cancer has worsened after at least one prior treatment will take part. The goal is to find the best dose and see how well the combination works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.